1. Home
  2. NWN vs SNDX Comparison

NWN vs SNDX Comparison

Compare NWN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NWN

Northwest Natural Holding Company

N/A

Current Price

$52.39

Market Cap

2.1B

Sector

Utilities

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$24.06

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NWN
SNDX
Founded
1859
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
NWN
SNDX
Price
$52.39
$24.06
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$52.50
$84.17
AVG Volume (30 Days)
273.4K
1.3M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
3.83%
N/A
EPS Growth
36.45
11.56
EPS
2.77
N/A
Revenue
$1,289,363,000.00
$172,352,000.00
Revenue This Year
$8.97
$112.05
Revenue Next Year
$4.27
$51.24
P/E Ratio
$18.55
N/A
Revenue Growth
11.83
627.84
52 Week Low
$38.94
$8.59
52 Week High
$53.66
$25.44

Technical Indicators

Market Signals
Indicator
NWN
SNDX
Relative Strength Index (RSI) 58.60 64.33
Support Level $45.72 $19.46
Resistance Level $53.61 $25.16
Average True Range (ATR) 1.24 1.09
MACD -0.15 0.04
Stochastic Oscillator 61.26 70.05

Price Performance

Historical Comparison
NWN
SNDX

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: